Innovations and recent trends in the treatment of ADHD.
Initiatives to develop better-tolerated, more efficacious pharmacological agents with improved drug delivery systems have driven recent research in attention-deficit hyperactivity disorder (ADHD). While stimulants are the primary pharmacotherapy for ADHD, these drugs have a limited duration of action and a subset of patients will either fail to respond to these medications or have side effects that preclude their use. The development of atomoxetine, the first nonstimulant approved for ADHD, has been followed by additional innovative research, such as the methylphenidate transdermal system, modafinil, NRP-104 and cholinergic agents. This review highlights some of the recent trends in ADHD treatment and the current status of promising treatment options that may help to shape the future of ADHD treatment.
Madaan
Vishal
V
Child and Adolescent Psychiatry, Creighton University-University of Nebraska Medical Center, Omaha, NE, USA. vishalmadaan@creighton.edu
Kinnan
Shannon
S
Daughton
Joan
J
Kratochvil
Christopher J
CJ
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends*; D006801:Humans; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends*; D011619:Psychotropic Drugs / Q000627:therapeutic use*
D000316:Adrenergic alpha-Agonists; D000928:Antidepressive Agents; D000697:Central Nervous System Stimulants; D011619:Psychotropic Drugs